Extension of Hematopoietic Progenitor Cell (HPC) Procurement Subsidy Scheme
From 1 January 2020, the Bone Marrow Donor Programme (BMDP) is extending its Hematopoietic Progenitor Cells (HPC) Procurement Subsidy Scheme to foreign spouses of Singaporean or Permanent Resident seeking treatment in Singapore.
There are 3 tiers of subsidies available for patients:
Tier 1: HPC Procurement Subsidy – A lump sum will be provided to patients to offset the HPC product cost. This is applicable for patients seeking treatment in both private and public hospitals.
Tier 2: Additional HPC Procurement Subsidy – In addition to T1 subsidy, patients may be eligible to apply for T2 subsidy, which subsidises up to 65% of the total HPC product cost. T2 subsidy is provided according to Ward Classes, i.e. the same basis that governs patient subsidies in public hospitals in Singapore.
Tier 3: Supplementary HPC Procurement Subsidy – This option is for needy patients staying in subsidised wards (B2 and below) and can cover up to 100% of HPC product cost, subject to recommendation put forth by an accredited Medical Social Worker (MSW) and BMDP’s approval.
In the extension of HPC Procurement Subsidy Scheme, foreign spouses of Singaporean or Permanent Resident will now be eligible to apply for Tier 2 Subsidy, subject to the patient’s eligibility and recommendation from the hospital’s MSW.
With the HPC Procurement Subsidy Scheme,
- Singaporean / Permanent Resident patients can receive up to 100% subsidy for the procurement of the HPC product
- Foreign Spouse to Singaporean / Permanent Resident can receive up to 60% subsidy for the procurement of the HPC product
Below are three examples to illustrate the computation of subsidies provided to patients:
How to apply?
Please approach your medical team for assistance. Your medical team will send your application to BMDP on your behalf. For more information, please refer to the Frequently Asked Questions.
For further enquiries, please email to firstname.lastname@example.org.
Related: New Patient Subsidy Fund
(Last Updated: 16 January 2020)